Understanding current therapies in metastatic melanoma

Simple item page
dc.contributor.authorRodriguez, Rocio
dc.contributor.authorPara, Angela
dc.contributor.authorGonzalez, Sergio
dc.contributor.authorMolgo, Montserrat
dc.contributor.authorDroppelmann, Nicolas
dc.contributor.authorAcevedo, Francisco
dc.contributor.authorPena, Jose
dc.contributor.authorUribe, Pablo
dc.date.accessioned2024-01-10T13:09:52Z
dc.date.available2024-01-10T13:09:52Z
dc.date.issued2016
dc.description.abstractCutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen- 4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.
dc.format.extent11 páginas
dc.fuente.origenWOS
dc.identifier.eissn0717-6163
dc.identifier.issn0034-9887
dc.identifier.pubmedidMEDLINE:28394962
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/77691
dc.identifier.wosidWOS:000390353000011
dc.information.autorucMedicina;Acevedo F;S/I;119540
dc.information.autorucMedicina;Droppelmann N;S/I;182477
dc.information.autorucMedicina;Gonzalez S;S/I;99856
dc.information.autorucMedicina;Molgo M;S/I;100088
dc.information.autorucMedicina;Para A;S/I;195751
dc.information.autorucMedicina;Pena J ;S/I;132734
dc.information.autorucMedicina;Rodriguez R ;S/I;195746
dc.information.autorucMedicina;Uribe P;S/I;9032
dc.issue.numero11
dc.language.isoes
dc.nota.accesoSin adjunto
dc.pagina.final1458
dc.pagina.inicio1448
dc.publisherSOC MEDICA SANTIAGO
dc.revistaREVISTA MEDICA DE CHILE
dc.rightsregistro bibliográfico
dc.subjectCTLA-4 Antigen
dc.subjectMelanoma
dc.subjectMolecular Targeted Therapy
dc.subjectPembrolizumab
dc.subjectProgrammed Cell Death 1 Receptor
dc.subjectBRAF INHIBITOR RESISTANCE
dc.subjectOPEN-LABEL
dc.subjectDRUG-RESISTANCE
dc.subjectMEK INHIBITION
dc.subjectPHASE-II
dc.subjectIMPROVED SURVIVAL
dc.subjectRANDOMIZED-TRIAL
dc.subjectSOLID TUMORS
dc.subjectVEMURAFENIB
dc.subjectNIVOLUMAB
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleUnderstanding current therapies in metastatic melanoma
dc.typeartículo
dc.volumen144
sipa.codpersvinculados119540
sipa.codpersvinculados182477
sipa.codpersvinculados99856
sipa.codpersvinculados100088
sipa.codpersvinculados195751
sipa.codpersvinculados132734
sipa.codpersvinculados195746
sipa.codpersvinculados9032
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Collections
Artículos de revistas